ここから本文です

MediciNova, Oregon Health & Science University Collaboration

In November 2017, MediciNova collaborated with the US Department of Veterans Affairs and Oregon Health & Science University to initiate a biomarker study for evaluating MN-166 (ibudilast) in methamphetamine (MA) use disorder. The proposed clinical trial would evaluate MN-166 (ibudilast) as a potential treatment for individuals diagnosed with MA use disorder with or without post-traumatic stress disorder (PTSD). This study had already completed FDA review.